Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41015 VSee Health, Inc. (Exact name of registrant as specified in its charter) Delaware 86-2970927 (State or other ...

Game-Changing AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare MarketVSee Health, Inc. (Nasdaq: VSEE): Major Clients Include NASA, U.S. Department of Health and Human Services, McKesson, DaVita and the Entire Nation of QatarHARRISON TOWNSHIP, N.J., April 2, 2025 /PRNewswire/ -- The healthcare industry is undergoing a significant transformation, and VSee Health, Inc. (Nasdaq: VSEE) is at the forefront, pioneering AI-driven telehealth solutions that are revolutionizing patient care. As a l ...

Exhibit 99.1 VSee Health Reports Third Quarter 2024 Revenue Up 131% Year-over-Year SAN JOSE, Calif. -- November 15, 2024 -- VSee Health, Inc. (Nasdaq: VSEE), a provider of comprehensive telehealth services that customize workflow streams and enhance patient care, today provided a business update and reported financial results for the three and nine months ended September 30, 2024. Financial & Business Highlights · Revenue was $3.4 million for the third quarter of 2024, up 131% over the third quarter of 2023 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41015 VSee Health, Inc. (Exact name of registrant as specified in its charter) Delaware 86-2970927 (State ...

Exhibit 99.1 VSee Health Provides a Business Update and Reports Second Quarter 2024 Financial Results BOCA RATON, Fla., September 23, 2024 – VSee Health, Inc. (Nasdaq: VSEE), a provider of comprehensive telehealth services that customize workflow streams and enhance patient care, today provided a business update and reported financial results for the three and six months ended June 30, 2024. Business Highlights · Successfully completed the de-SPAC transaction and now publicly traded as VSee Health, followin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41015 VSee Health, Inc. (Exact name of registrant as specified in its charter) Delaware 86-2970927 (State or o ...

Financial Performance - The net loss for the three months ended March 31, 2024, was $967,817, compared to a net loss of $1,894,642 for the same period in 2023, representing a 48.9% improvement[13]. - Basic and diluted net loss per share improved from $(0.45) in Q1 2023 to $(0.27) in Q1 2024[13]. - The company reported a loss from operations of $674,262 for the three months ended March 31, 2024, compared to a loss of $707,592 in the same period of 2023, showing a decrease of about 4.7%[13]. - Net cash used in operating activities was $335,318 for the three months ended March 31, 2024, slightly down from $340,667 in the same period of 2023[19]. - The effective tax rate for the Company was 0.0% for both the three months ended March 31, 2024, and 2023, due to a full valuation allowance on deferred tax assets[62]. Assets and Liabilities - Total current assets decreased from $1,863 million as of December 31, 2023, to $724 million as of March 31, 2024[10]. - Total assets increased slightly from $1,370.5 million to $1,387.2 million during the same period[10]. - Current liabilities rose from $7,984.4 million to $8,968.9 million, indicating a significant increase of approximately 12.3%[11]. - Total liabilities increased from $12,354.4 million to $13,338.9 million, reflecting a rise of approximately 7.9%[11]. - As of March 31, 2024, the Company had a cash balance of $724 and a working capital deficit of $8,968,207[49]. Business Combination and Future Plans - The company has extended the deadline to consummate a Business Combination to November 8, 2024, allowing for additional time to identify a target[29]. - The Company is required to complete its initial Business Combination by November 8, 2024, or face mandatory liquidation[49]. - The Company has the ability to extend the Business Combination period up to four times, each by an additional three months, for a total of twelve additional months[30]. - The Business Combination Agreement includes the merger of Merger Sub I with VSee and Merger Sub II with iDoc, with both becoming wholly owned subsidiaries of the Company[39]. - The Company has not commenced any significant operations and will not generate operating revenues until after completing its initial Business Combination[22]. Capital Raising and Financing - The company generated gross proceeds of $115,000,000 from its Initial Public Offering, which included the full exercise of the underwriter's over-allotment option[23]. - The Company intends to raise additional capital through loans or investments from the Sponsor or its stockholders to meet working capital needs[48]. - The Company has entered into a securities purchase agreement for Bridge Financing, issuing senior secured promissory notes totaling $2,222,222[92]. - The Company will issue a senior unsecured convertible note worth $500,000 to the investor at a fixed conversion price of $10.00 per share as a commitment fee[168]. Shareholder and Stock Information - A total of 579,157 shares of common stock were redeemed in connection with the 2023 Annual Meeting, leaving 114,966 shares subject to redemption[31]. - As of March 31, 2024, the common stock subject to possible redemption is valued at $7,395,349 after accounting for redemptions and accretion[60]. - The Company is authorized to issue 50,000,000 common shares, with 3,489,000 shares issued and outstanding as of March 31, 2024[171]. - The Company has received multiple notifications from Nasdaq regarding non-compliance with listing requirements, including a market value of listed securities below $50 million and a market value of publicly held shares below $15 million[40][41]. Debt and Interest Expenses - Interest expense on Bridge/Exchange Note decreased from $133,138 in Q1 2023 to $51,036 in Q1 2024, a reduction of approximately 61.7%[13]. - The Company recognized interest expense of $22,792 for the three months ended March 31, 2024, including $20,296 of default interest[91]. - The Company defaulted on the Bridge Notes, resulting in a total amount due of $2,523,744, including penalties and interest[148]. - The Exchange Agreement recognized $1,579,927 in default interest due to the Bridge Investor[148]. Regulatory and Compliance - The Company is classified as an "emerging growth company" and may take advantage of certain exemptions from reporting requirements[50]. - The Company has determined that its liquidity condition raises substantial doubt about its ability to continue as a going concern[49]. - The Inflation Reduction Act of 2022 imposes a 1% excise tax on stock repurchases, effective January 1, 2023, which may affect the Company's future financial strategies[79]. Warrants and Securities - As of March 31, 2024, there are 12,057,000 warrants issued and outstanding, each entitling the holder to purchase one share of common stock at $11.50[177]. - The warrants may be called for redemption at $0.01 per warrant if the stock price exceeds $18.00 for 20 trading days within a 30-day period[179]. - The Company must reserve sufficient shares for the exercise of the Bridge Warrants and will amend its Certificate of Incorporation as necessary[188]. - The Extension Warrants are exercisable for a period of five years from the date of issuance[200].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ________________ Commission file number: 001 - 41015 DIGITAL HEALTH ACQUISITION CORP. (Exact name of registrant as specified in its charter) Dela ...

Financial Position - As of September 30, 2023, total assets amounted to $8,137,649, an increase from $7,634,367 as of December 31, 2022[12]. - Current liabilities increased to $5,022,029 from $3,295,614, primarily due to higher accounts payable and accrued expenses[13]. - Total stockholders' deficit as of September 30, 2023, was $(9,148,594), an increase from $(7,426,596) as of December 31, 2022[14]. - The Company had cash of $507 at the end of the period, a significant decrease from $44,970 at the end of September 30, 2022[21]. - As of September 30, 2023, the Company had a cash balance of $507 and a working capital deficiency of $8,154,992[57]. - The Company has significant cash balances at financial institutions, which did not exceed the federally insured limit of $250,000[77]. Net Loss and Earnings - The net loss for the three months ended September 30, 2023, was $78,287, compared to a net loss of $820,759 for the same period in 2022[15]. - For the nine months ended September 30, 2023, the net loss was $1,552,805, a decrease from a net loss of $2,007,578 for the same period in 2022, representing a 22.5% improvement[21]. - Basic and diluted net income per share for the three months ended September 30, 2023, was $0.02, while it was $(0.05) for the same period in 2022[15]. Business Combination and Future Operations - The company anticipates future operations will be influenced by the completion of the Proposed Business Combination, although risks remain[9]. - The Company has extended the deadline for completing its initial Business Combination to November 8, 2024, allowing for additional time to identify a target business[32]. - The Company has entered into a Business Combination agreement with VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc.[36]. - The Company has not yet completed the initial Business Combination and has waived certain redemption rights related to this process[34]. - The Business Combination is subject to stockholder approvals from DHAC, VSee, and iDoc, as well as regulatory conditions[110]. Trust Account and Proceeds - The company’s investments held in the Trust Account increased to $8,119,642 from $7,527,369[12]. - The Trust Account held an anticipated amount of $10.65 per public share as of October 26, 2022, following a deposit of $350,000 for an extension[32]. - Approximately $116,725,000 of the net proceeds from the Initial Public Offering and certain proceeds from the Private Placement were placed in a Trust Account, invested in U.S. government securities[203]. Compliance and Listing - As of September 30, 2023, the Company received a notification from Nasdaq indicating that its market value of listed securities was below the $50 million requirement for continued listing[38]. - The Company has until November 20, 2023, to regain compliance with the market value of publicly held shares requirement of $15 million[41]. - The Company is subject to potential delisting from Nasdaq Global due to non-compliance with listing standards[42]. Initial Public Offering - The Company generated gross proceeds of $115,000,000 from its Initial Public Offering, which included the full exercise of the underwriter's over-allotment option[25]. - The Company recorded transaction costs of $6,877,164 related to its Initial Public Offering, which included underwriting fees and other offering costs[27]. - The Company sold 11,500,000 units in its Initial Public Offering at a purchase price of $10.00 per unit, including a full exercise of the underwriters' over-allotment option of 1,500,000 units[87]. Debt and Financing - The Company issued a promissory note to SCS Capital Partners LLC in the amount of $565,000, which is due at the closing of the business combination[48]. - The Company issued an unsecured promissory note to the Sponsor for $350,000, which was deposited into the trust account to extend the time available for completing a business combination[94]. - The Company recorded an amortizable debt discount of $443,665 related to the Bridge Notes, including various components such as financing costs and fair value of shares and warrants[126]. Shareholder Information - The Company redeemed 10,805,877 shares of common stock in connection with a stockholder meeting, leaving 4,156,123 shares issued and outstanding[29]. - The Company has 2,875,000 founder shares outstanding after the forfeiture of 1,437,500 shares[90]. - The company has 12,057,000 warrants issued and outstanding as of September 30, 2023, each warrant entitles the holder to purchase one share of common stock at a price of $11.50[146]. Tax and Regulatory Matters - The effective tax rate for the three months ended September 30, 2023, was 0.0%, compared to 11.25% for the same period in 2022[70]. - The Inflation Reduction Act of 2022 imposes a 1% excise tax on stock repurchases by publicly traded corporations, effective January 1, 2023, which may impact the Company's cash available for business combinations[85]. Risk Factors - The Company has substantial doubt about its ability to continue as a going concern due to mandatory liquidation and dissolution on February 8, 2024[57]. - Management continues to evaluate the impact of the COVID-19 pandemic and current wars on the industry, noting potential negative effects on financial position and operations[84].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41015 DIGITAL HEALTH ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) | --- | |-------| | | | | | ...